Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE

Vibeke Strand, Namita Tundia, Martin Bergman, Andrew Ostor, Patrick Durez, In-Ho Song, Jeffrey Enejosa, Casey Schlacher, Yan Song, Roy Fleischmann, Vibeke Strand, Namita Tundia, Martin Bergman, Andrew Ostor, Patrick Durez, In-Ho Song, Jeffrey Enejosa, Casey Schlacher, Yan Song, Roy Fleischmann

Abstract

Objective: To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to MTX (MTX-IR).

Methods: PROs in patients receiving upadacitinib (15 mg QD), placebo, or adalimumab (40 mg EOW) while on background MTX were evaluated over 48 weeks. PROs included Patient Global Assessment of Disease Activity (PtGA) and pain by visual analogue scale (VAS), the HAQ Disability Index (HAQ-DI), the 36-Item Short Form Survey (SF-36), morning (AM) stiffness duration and severity, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and work instability. Least squares mean (LSM) changes and proportions of patients reporting improvements ≥ minimal clinically important differences (MCIDs) and scores ≥ normative values were evaluated.

Results: Upadacitinib and adalimumab resulted in greater LSM changes from baseline vs placebo across all PROs (P < 0.05) at week 12, and pain and AM stiffness severity (P < 0.05) at week 2. More upadacitinib- vs placebo-treated (P < 0.05) and similar percentages of upadacitinib- vs adalimumab-treated patients reported improvements ≥ MCID across all PROs at week 12. Upadacitinib vs adalimumab resulted in greater LSM changes from baseline in PtGA, pain, HAQ-DI, stiffness severity, FACIT-F, and the SF-36 Physical Component Summary (PCS) (all P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients reported scores ≥ normative values in HAQ-DI and SF-36 PCS (P < 0.05) at week 12. More upadacitinib- vs adalimumab-treated patients maintained clinically meaningful improvements in PtGA, pain, HAQ-DI, FACIT-F, and AM stiffness through 48 weeks.

Conclusion: In MTX-IR patients with RA, treatment with upadacitinib resulted in statistically significant and clinically meaningful improvements in PROs equivalent to or greater than with adalimumab.

Trial registration: ClinicalTrials.gov, https://ichgcp.net/clinical-trials-registry/NCT02629159" title="See in ClinicalTrials.gov">NCT02629159.

Keywords: DMARDs; inflammation; outcome measures; quality of life; rheumatoid arthritis.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
SF-36 domain scores at baseline and week 12 for all treatment groups relative to age- and gender-matched normative values ADA, adalimumab; A/G norms, age- and gender-matched normative values; BL, baseline; BP, bodily pain; GH, general health; MH, mental health; PBO, placebo; PF, physical functioning; RE, role-emotional; RP, role-physical; SF-36, 36-Item Short-Form Health Survey; SF, social functioning; UPA, upadacitinib; VT, vitality.
Fig . 2
Fig. 2
Patients reporting PRO score improvements ≥ MCID at week 12 aP < 0.05 for UPA vs PBO; bP < 0.05 for UPA vs ADA. ADA, adalimumab; AM, morning; BP, bodily pain; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; GH, general health; HAQ-DI, HAQ-Disability Index; MCID, minimal clinically important difference; MCS, Mental Component Summary; MH, mental health; NNT, number needed to treat; PBO, placebo; PCS, Physical Component Summary; PF, physical functioning; PRO, patient-reported outcome; PtGA, Patient’s Global Assessment of Disease Activity; RA-WIS; Work Instability Scale for RA; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, 36-Item Short-Form Health Survey; UPAD, upadacitinib; VAS, visual analog scale; VT, vitality.
Fig . 3
Fig. 3
Patients reporting PRO scores ≥ normative values at baseline and week 12 aP < 0.01 for UPAD vs PBO; bP < 0.05 for UPA vs ADA. ADA, adalimumab; BL, baseline; BP, bodily pain; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; GH, general health; HAQ-DI, HAQ-Disability Index; MCS, Mental Component Summary; MH, mental health; PBO, placebo; PCS, Physical Component Summary; PF, physical functioning; PRO, patient-reported outcome; RA-WIS, Work Instability Scale for RA; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, 36-Item Short-Form Health Survey; UPA, upadacitinib; VT, vitality.

References

    1. Smolen JS, Aletaha D, McInnes IB.. Rheumatoid arthritis. Lancet 2016;388:2023–38.
    1. Halls S, Dures E, Kirwan J. et al. Stiffness is more than just duration and severity: a qualitative exploration in people with rheumatoid arthritis. Rheumatology (Oxford) 2015;54:615–22.
    1. Hewlett S, Cockshott Z, Byron M. et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697–702.
    1. Pollard LC, Choy EH, Gonzalez J. et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006;45:885–9.
    1. Westhoff G, Buttgereit F, Gromnica-Ihle E. et al. Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology (Oxford) 2008;47:980–4.
    1. Strand V, Khanna D.. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol 2010;28:S32–40.
    1. Singh JA, Saag KG, Bridges SL Jr. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
    1. Smolen JS, Landewe RBM, Bijlsma JWJ. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
    1. Aletaha D, Smolen JS.. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360–72.
    1. Smolen JS, Landewe R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
    1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc., 2019.
    1. European Medicines Agency: RINVOQ SmPC. North Chicago, IL: AbbVie, Inc., 2019.
    1. Fleischmann RM, Genovese MC, Enejosa JV. et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 2019;78:1454–62.
    1. Burmester GR, Kremer JM, van den Bosch F. et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:2503–12.
    1. Genovese MC, Fleischmann R, Combe B. et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018;391:2513–24.
    1. Smolen JS, Pangan AL, Emery P. et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019;393:2303–11.
    1. Strand V, Boers M, Idzerda L. et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720–7.
    1. Sanderson T, Morris M, Calnan M. et al. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res 2010;62:640–6.
    1. Strand V, Pope J, Tundia N. et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther 2019;21:272.
    1. Strand V, Schiff M, Tundia N. et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther 2019;21:263.
    1. Fleischmann R, Pangan AL, Song IH. et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019;71:1788–800.
    1. Wells GA, Boers M, Shea B. et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016–24.
    1. Kitchen H, Hansen B, Abetz L. et al. Patient-reported outcome measures for rheumatoid arthritis: minimal important differences review. Arthritis Rheum 2013;65(Suppl 10):abstract 2268.
    1. Fleischmann R, Weinblatt ME, Schiff M. et al. Patient-reported outcomes from a two-year head-to-head comparison of subcutaneous abatacept and adalimumab for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:907–13.
    1. Bruce B, Fries JF.. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14–18.
    1. Krishnan E, Sokka T, Hakkinen A. et al. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953–60.
    1. Cella D, Yount S, Sorensen M. et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811–9.
    1. Ware JE, Sherbourne CD.. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
    1. Busija L, Pausenberger E, Haines TP. et al. Adult measures of general health and health-related quality of life: medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL. ). Arthritis Care Res (Hoboken) 2011;63:S383–412.
    1. Wells G, Li T, Maxwell L. et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008;67:260–5.
    1. Strand V, Crawford B, Singh J. et al. Use of “spydergrams” to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800–4.
    1. Orbai AM, Smith KC, Bartlett SJ. et al. “Stiffness has different meanings, I think, to everyone”: examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:1662–72.
    1. Revicki D, Cifaldi MA, Safikhani S. et al. AB0266: Responsiveness and minimal important difference of the rheumatoid arthritis–work instability scale (RA-WIS). Ann Rheum Dis 2013;72:A867.
    1. Fleischmann R, Mysler E, Hall S. et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017;390:457–68.
    1. Keystone EC, Taylor PC, Tanaka Y. et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis 2017;76:1853–61.
    1. Strand V, Mysler E, Moots RJ. et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open 2019;5:e001040.
    1. Taylor PC, Keystone EC, van der Heijde D. et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652–62.
    1. Heiberg T, Kvien TK.. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002;47:391–7.
    1. OLUMIANT [package insert]. Indianapolis, IN: Eli Lilly and Company, 2019.
    1. Fautrel B, Kirkham B, Pope JE. et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J Clin Med 2019;8:1394.
    1. Strand V, Kremer J, Wallenstein G. et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther 2015;17:307.
    1. van Tuyl LH, Sadlonova M, Hewlett S. et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis 2017;76:855–61.
    1. Kirwan JR, Hewlett S.. Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 2007;34:1171–3.
    1. Taylor PC, Moore A, Vasilescu R. et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016;36:685–95.
    1. Wolfe F, Michaud K.. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum 2009;61:667–73.
    1. Lacaille D, White MA, Backman CL. et al. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients’ perspective. Arthritis Rheum 2007;57:1269–79.
    1. Genovese M, Westhovens R, Meuleners L. et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther 2018; 20:57.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa